INmune Bio, Inc. appointed R. Duane Clark II and James Sapirstein as independent directors on September 8, 2026, increasing the Board size to seven members. Both executives bring over 40 years of biopharmaceutical leadership; Mr. Clark currently serves as General Manager for U.S. Rare Diseases at Sanofi, while Mr. Sapirstein is CEO of Cocrystal Pharma and former CEO of Entero Therapeutics. Each director received an initial option to purchase 100,000 shares vesting over three years, a $50,000 annual cash retainer payable quarterly, and standard indemnification agreements. The appointments aim to strengthen the Board's capabilities in rare-disease commercialization for Ebstrocel™ and business development for strategic partnerships as the company advances its late-stage pipeline toward potential regulatory filings and commercialization. INmune Bio is a late-stage biotechnology company focused on developing treatments targeting the innate immune system for inflammation, immunology, and neuroinflammation.

INmune Bio Inc. announced the receipt of approximately $4.2 million in research and development cash rebates from Australia on July 30, 2026. This follows a separate rebate of approximately $0.4 million received from the United Kingdom in June 2026, bringing total non-dilutive proceeds to roughly $4.6 million. The company states that these funds strengthen its balance sheet and extend its cash runway without requiring additional equity issuance. INmune Bio is a late-stage biotechnology company focused on developing treatments targeting the innate immune system for inflammation and immunology.

On June 30, 2026, INmune Bio, Inc. entered into a warrant inducement offer letter and an amendment to common stock purchase warrants to extend maturity dates and induce holders to exercise 50% of their April 2024 Warrants at a reduced exercise price of $1.40 per share, down from $1.95. The company expects to receive approximately $905,957 in cash consideration for these exercises. INmune Bio, Inc. is a biotechnology company focused on developing immune-modulating therapies.

Inmune Bio, Inc. received official meeting minutes from a pre-Marketing Authorization Application (pre-MAA) Scientific Advice meeting with the UK Medicines & Healthcare products Regulatory Agency (MHRA) regarding CORDStrom (Ebstrocel) for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB). Inmune Bio, Inc. is a biotechnology company focused on developing and commercializing immune-modulating products.

On June 16, 2026, stockholders approved the Third Amended and Restated 2021 Stock Incentive Plan, increasing the number of issuable common shares from 6,500,000 to 9,158,525. The approval includes an evergreen provision from 2027 through 2031 that automatically increases reserved shares annually by the lesser of 10% of outstanding common stock as of December 31 of the preceding year or a smaller amount determined by the board. Stockholders also elected the board of directors and ratified CBIZ CPAs P.C. as the independent auditor for the fiscal year ending December 31, 2026. Inmune Bio is a biotechnology company developing therapies for neurodegenerative diseases.